Study of Livmoniplimab and Budigalimab for Liver Cancer (HCC)
This study is looking at new ways to treat hepatocellular carcinoma (HCC), a type of liver cancer. Researchers are testing an investigational drug called livmoniplimab in combination with another investigational drug, budigalimab. They want to find the best dose, understand any side effects, and see how well this combination works to shrink tumors or slow the cancer's growth. You might receive livmoniplimab plus budigalimab, or other approved drug combinations like atezolizumab with bevacizumab, or tremelimumab with durvalumab. The study is open to adults aged 18 and older who have advanced or unresectable HCC. The main goals are to see how many participants respond to treatment and how long they live. This study is currently recruiting 660 participants.
- Study design
- This interventional study has two stages and involves 660 participants. In Stage 1, participants will be randomly assigned to one of three treatment groups.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to approximately 56 months (about 4 years and 8 months) to assess treatment response and overall survival.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
At a glance
Conditions
NCT06109272
Where you'd take part
This study runs at 37 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Baylor Scott and White Research Institute /ID# 260853
Dallas, Texasstudy coordinator listed
Recruiting
Henry Ford Hospital /ID# 255803
Detroit, Michiganstudy coordinator listed
Recruiting
Hospital Universitario Miguel Servet /ID# 255774
Zaragoza, Spainstudy coordinator listed
Recruiting
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 256681
Palermo, Italyno site contact published
Recruiting
CHU Grenoble - Hopital Michallon /ID# 256627
La Tronche, Isere, Franceno site contact published
Recruiting
City of Hope /ID# 261468
Duarte, Californiano site contact published
Recruiting
City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669
Irvine, Californiano site contact published
Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 265506
Rome, Roma, Italyno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- ABBVIE INC. · STUDY_DIRECTOR · AbbVie
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Stage 1: Best Overall Response (BOR) per InvestigatorThrough Study Completion, Up to Approximately 56 Months
BOR is defined as a participant achieving confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by investigators at any time prior to subsequent anticancer therapy.
- Stage 2: Overall Survival (OS)Through Study Completion, Up to Approximately 56 Months
OS is defined as the time from randomization until death from any cause